Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana LinfomiCarlo Visco, Umberto Vitolo, Annalisa Chiappella et al.|The Lancet Haematology|2016Cited by 139
<i>KMT2D</i> mutations and <i>TP53</i> disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL studySimone Ferrero, Gianluca Gaïdano, Valeria Spina et al.|Haematologica|2019Cited by 137